Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 Update
M A Martin, James M. Hoffman, Robert R. Freimuth et al. · Clinical Pharmacology & Therapeutics · 2014
The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing were originally published in April 2012. We reviewed recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplementary Material online and included additional resources for applying CPIC guidelines to the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).
Cited by 153 works. doi:10.1038/clpt.2014.38 Open-access PDF
Authors
- James M. Hoffman
- Robert R. Freimuth
- Teri E. Klein
- Betty J. Dong
- Munir Pirmohamed
- J K Hicks
- Mark R. Wilkinson
- David W. Haas
- Deanna L. Kroetz
References
- CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network
- Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Carbamazepine Dosing
- The Emerging Role of Electronic Medical Records in Pharmacogenomics
- The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real-World Implementation
- Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing
- Leveraging the electronic health record to implement genomic medicine
- HLA-B*57:01+ abacavir-naive individuals have specific T cells but no patch test reactivity